Regeneron Pharmaceuticals
REGN
1,019 hedge funds and large institutions have $54.5B invested in Regeneron Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 133 funds opening new positions, 410 increasing their positions, 325 reducing their positions, and 73 closing their positions.
82% more first-time investments, than exits
New positions opened: 133 | Existing positions closed: 73
26% more repeat investments, than reductions
Existing positions increased: 410 | Existing positions reduced: 325
10% more capital invested
Capital invested by funds: $49.6B → $54.5B (+$4.86B)
5% more funds holding
Funds holding: 972 → 1,019 (+47)
1.06% more ownership
Funds ownership: 84.95% → 86.01% (+1.1%)
6% less funds holding in top 10
Funds holding in top 10: 18 → 17 (-1)
20% less call options, than puts
Call options by funds: $1.16B | Put options by funds: $1.44B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$251M |
| 2 |
BlackRock
New York
|
+$207M |
| 3 |
JP Morgan Chase
New York
|
+$195M |
| 4 |
Amundi
Paris,
France
|
+$140M |
| 5 |
SGH
Sivik Global Healthcare
Greenwich,
Connecticut
|
+$99.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$428M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$235M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$177M |
| 4 |
Neuberger Berman Group
New York
|
-$108M |
| 5 |
HM
HealthCor Management
New York
|
-$106M |
REGN Hedge Fund Activity: Q3 2021 in Review
1,019 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2021, worth a combined $54.5B — up 9.8% from $49.6B a quarter earlier.
Buyers outnumbered sellers: 133 funds opened new REGN positions and 73 closed out — a net gain of 60 holders — while 410 added to existing stakes and 325 trimmed.
The largest buyer was Putnam Investments, adding an estimated $251M. The largest seller was Wellington Management Group, cutting an estimated $428M.
- 1,019 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2021, up from 972 in Q2 2021.
- Funds reported $54.5B of Regeneron Pharmaceuticals stock for Q3 2021, up 9.8% quarter-over-quarter.
- 133 funds opened new Regeneron Pharmaceuticals positions in Q3 2021 and 73 closed out, a net change of +60 holders.
- The largest Regeneron Pharmaceuticals buyer in Q3 2021 was Putnam Investments, an estimated $251M added.
- The largest Regeneron Pharmaceuticals seller in Q3 2021 was Wellington Management Group, an estimated $428M sold.
Based on aggregated 13F filings for Q3 2021.